412 filings
S-3
ZVRA
Zevra Therapeutics Inc
Shelf registration
4 Jun 24
5:13pm
8-K
ZVRA
Zevra Therapeutics Inc
3 Jun 24
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial
5:06pm
8-K
ZVRA
Zevra Therapeutics Inc
13 May 24
Submission of Matters to a Vote of Security Holders
4:47pm
10-Q
2024 Q1
ZVRA
Zevra Therapeutics Inc
Quarterly report
9 May 24
4:34pm
8-K
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
DEFA14A
i1w23cb9
29 Apr 24
Additional proxy soliciting materials
7:49am
424B3
0ol5wk1w rkcab3sjri2
10 Apr 24
Prospectus supplement
4:23pm
8-K
uba56
10 Apr 24
Entry into a Material Definitive Agreement
7:46am
EFFECT
f1wdoq3wqa4g
9 Apr 24
Notice of effectiveness
12:15am
DEFA14A
7b3l42e 51db
3 Apr 24
Additional proxy soliciting materials
4:17pm
8-K
kgixjibnba zh5ntc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K
st7awmt8jp iz
26 Mar 24
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
8:28pm
8-K
qfdv nwj4
5 Mar 24
Regulation FD Disclosure
7:34am
8-K
5k9e8b2m9g 70rxrst
4 Mar 24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:24am
8-K
kfezxfa31dc tg93rw
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K/A
kgdwjjlz1vbs3a ondan
5 Feb 24
Financial Statements and Exhibits
12:00am